Efficacy of escitalopram in patients with severe depression: A pooled analysis

International Journal of Clinical Practice

Volumn 59, Issue 3, 2005, Pages 268-275

  Llorca, P M ^a   Azorin, J M ^b   Despiegel, N ^c   Verpillat, Patrice ^c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c Lundbeck   (France)

Author keywords

Efficacy; Escitalopram; Pooled analysis; Severe depression; SSRI

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 14844365616     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00440.x     Document Type: Article

References (30)

1. American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993; 150 (Suppl. 4): S1-S26.
2. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994; 55 (Suppl. A): 62-8.
3. Thase ME. Treatment of severe depression. J Clin Psychiatry 2000; 61 (Suppl. 1): 17-25.
4. Keitner GI, Ryan CE, Miller IW et al. Recovery and major depression: factors associated with twelve-month outcome. Am J Psychiatry 1992; 149: 93-9.
5. Montgomery SA, Lecrubier Y. Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 1999; 9: 259-64.
6. Wade A, Michael LO, Bang HK. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102.
7. Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients Poster presented at the 3rd International Forum on Mood and Anxiety Disorders (IFMAD), Monte Carlo, Monaco 27-30 November 2002. 2002: 243 (P05).
8. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-7.
9. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-6.
10. Montgomery SA, Loft H, Sanchez C et al. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 2001; 88: 282-6.
11. Auquier P, Robitail S, Llorca P et al. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychol Clin Pract 2003; 7: 259-68.
12. Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 1999; 60 (Suppl. 4): 14-21.
13. Forest Laboratories I. Flexible dose comparison of the safety and efficacy of escitalopram, citalopram and placebo in the treatment of major depressive disorder. Forest Laboratories Inc, New York, NY, USA 2003 (Unpublished data).
14. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
16. Snaith RP, Harrop FM, Newby DA et al. Grade scores of the Montgomery-Asberg Depression and the Clinical Anxiety Scales. Br J Psychiatry 1986; 148: 599-601.
17. Beasley CM Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 1993; 5: 199-207.
18. Arminen SL, Ikonen U, Pulkkinen P et al. A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 1994; 89 382-9.
19. Bowden CL, Schatzberg AF, Rosenbaum A et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993; 13: 305-11.
20. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 1999; 60: 326-35.
21. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrum 2002; 7: 40-4.
22. Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003; 45: 167-73.
23. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238-45.
24. Fabre V, Hamon M. Mechanisms of action of antidepressants: new data from Escitalopram. Encephale 2003; 29: 259-65.
25. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001; 15: 765-76.
26. Hirschfeld RM. Controversies in the diagnosis and treatment of severe depression. J Clin Psychiatry 1996; 57: 554-61.
27. Nierenberg AA. The treatment of severe depression: Is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 1994; 55 (Suppl. A): 55-9.
28. Angst J, Delini-Stula A, Stahl M et al. Is a cut-off score a suitable measure of treatment outcome in shirt-trem trials in depression? A methodological meta-analysis. Hum Psychopharmacol 1993; 8: 311-7.
29. Schatzberg AF. Treatment of severe depression with the selective serotonin reuptake inhibitors. Depress Anxiety 1996; 4 182-9.
30. Mendlewicz J. Efficacy of fluvoxamine in severe depression. Drugs 1992; 43 (Suppl. 2): 32-7.